Patients who received human recombinant erythropoietin in the days before heart surgery needed less transfused blood, according to findings presented at a thoracic surgery meeting. The randomized prospective study looked at about 600 cardiac surgery patients. Erythropoietin is a viable but underutilized tool for patient blood management, said Dr. Luca Weltert of the European Hospital in Rome.

Related Summaries